ArticleAntimicrobial agents and chemotherapy2006
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 96 citations in OpenAlex.
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Critical care (London, England) · 2023Review
- Review
- Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- The Flo Adhesin Family.Pathogens (Basel, Switzerland) · 2021Review
- A Second-Generation Fungerp Analog, SCY-247, Shows PotentAntimicrobial agents and chemotherapy · 2021Article
- AJournal of fungi (Basel, Switzerland) · 2021Article
- Cellular apoptosis: An alternative mechanism of action for caspofungin againstCurrent medical mycology · 2019Article
- Candida parapsilosis: from Genes to the Bedside.Clinical microbiology reviews · 2019Review
- Candida sp. Infections in Patients with Diabetes Mellitus.Journal of clinical medicine · 2019Review
- Portrait of Matrix Gene Expression in Candida glabrata Biofilms with Stress Induced by Different Drugs.Genes · 2018Article
- Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.The Journal of antimicrobial chemotherapy · 2017Article
- Candida glabrata Biofilms: How Far Have We Come?Journal of fungi (Basel, Switzerland) · 2017Review
- Outcome of Candida Parapsilosis Complex Infections Treated with Caspofungin in Children.Mediterranean journal of hematology and infectious diseases · 2016Article
- Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Antimicrobial agents and chemotherapy · 2015Article
- Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.Journal of clinical microbiology · 2015Article
- Epidemiology of echinocandin resistance inCurrent fungal infection reports · 2014Article
- Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.Antimicrobial agents and chemotherapy · 2014Article
- Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activity of caspofungin (CAS) was investigated against 28 yeast isolates belonging to Candida albicans (n = 5), Candida guilliermondii (n = 10), and Candida parapsilosis (n = 13). CAS MICs obtained by broth dilution and Etest methods clearly showed a rank order of susceptibility to the echinocandin compound with C. albicans > C. parapsilosis > C. guilliermondii. Similarly, time-kill assays performed on selected isolates showed that CAS was fungistatic against C. albicans and C. parapsilosis, while it did not exert any activity against C. guilliermondii. In a murine model of systemic candidiasis, CAS given at doses as low as 1 mg/kg of body weight/day was effective at reducing the kidney burden of mice infected with either C. albicans or C. guilliermondii isolates. Depending on the isolate tested, mice infected with C. parapsilosis responded to CAS given at 1 and/or 5 mg/kg/day. However, the overall CFU reduction for C. guilliermondii and C. parapsilosis was approximately 100-fold less than that for C. albicans. Our study shows that CAS was active in experimental systemic candidiasis due to C. guilliermondii and C. parapsilosis, but this activity required relatively high drug dosages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.